Business Context and Reporting Period
This Form 8-K Current Report, dated July 14, 2024, details a material definitive agreement between Milestone Pharmaceuticals Inc. (the "Company") and Alta Fundamental Advisers LLC ("Alta"). The filing addresses the resolution of a shareholder nomination contest, the expansion of the Board of Directors, and the withdrawal of Alta's intent to nominate directors for the 2024 Annual Meeting.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and shareholder relations. The only financial data disclosed relates to director compensation:
- Annual Cash Compensation: $42,500 per new director.
- Equity Grant: Options to purchase up to 80,000 common shares per new director, vesting monthly over three years.
Material Changes Versus Prior Period
The following material changes to the Company's governance structure were implemented effective July 14, 2024:
- Board Expansion: The Board size increased to nine (9) directors.
- New Appointments: Stuart M. Duty and Andrew R. Saik were appointed as independent directors. Mr. Duty joined the Nominating and Corporate Governance Committee, and Mr. Saik joined the Audit Committee.
- Future Appointment: The Company agreed to appoint one additional mutually agreeable independent director prior to September 6, 2024.
- Shareholder Withdrawal: Alta irrevocably withdrew its notice to nominate five directors for the 2024 Annual Meeting.
- Director Resignations: Debra K. Liebert and Richard Pasternak, MD, announced they will not stand for reelection at the 2024 Annual Meeting. Following the meeting and the appointment of the new director, the Board size will decrease to eight (8) directors.
Guidance, Outlook, and Management Commentary
Cooperation Agreement Terms:
- Proxy Support: The Company will include the two new directors on its slate for the 2024 and 2025 Annual Meetings and solicit proxies for their election.
- Voting Commitment: Alta agreed to vote its shares in accordance with the Board's recommendations on all proposals prior to the "Termination Date" (conclusion of the 2025 Annual Meeting), with exceptions for proposals recommended against by ISS or Glass Lewis, or regarding "Extraordinary Transactions."
- Replacement Mechanism: If a new director resigns before the Termination Date and Alta holds a Net Long Position of at least 4.0%, the parties will cooperate to appoint a replacement independent director.
- Duration: The agreement remains in effect until the Termination Date unless terminated earlier per its terms.
2024 Annual Meeting: Scheduled for August 28, 2024, via the Internet. The record date for shareholders was July 9, 2024.
Important Facts for Investor Verification
- Verify the full text of the Cooperation Agreement (Exhibit 10.1) for specific definitions of "Net Long Position" and "Extraordinary Transaction."
- Confirm the identity and independence status of the third director to be appointed by September 6, 2024.
- Monitor the 2024 Annual Meeting proxy materials to confirm the final slate of director nominees.
- Review the impact of the new equity grants (80,000 shares per director) on potential dilution.